Posted by Michael Wonder on 02 Jun 2021
Liquidia announces FDA acceptance of new drug application resubmission for LIQ861 (treprostinil) inhalation powder
2 June 2021 - Liquidia announced today that the U.S. FDA has accepted its new drug application resubmission for LIQ861 (treprostinil) inhalation powder to treat pulmonary arterial hypertension.
The FDA confirmed that the resubmission was a complete, class 2 response to the previous action letter issued on 24 November 2020. The FDA set a PDUFA goal date of 7 November 2021.
